TITLE

The Efficacy of Oral Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever in Iran

AUTHOR(S)
Mardani, M.; Jahromi, M. Keshtkar; Naieni, K. Holakouie; Zeinali, M.
PUB. DATE
June 2003
SOURCE
Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1613
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We compared the mortality rate among patients suspected of having Crimean-Congo hemorrhagic fever (CCHF) who received treatment with oral ribavirin and those who did not. Ninety-seven (69.8%) of 139 treated patients suspected of having CCHF survived, and 61 (88.9%) of 69 treated patients with confirmed CCHF survived. The efficacy of oral ribavirin was 80% among patients with confirmed CCHF and 34% among patients suspected of having CCHF. Considering the limitations of observational studies, we conclude that oral ribavirin is an effective treatment for the hemorrhagic form of CCHF.
ACCESSION #
10023873

 

Related Articles

  • Kırım Kongo kanamalı ateÅŸinin intrauterin ve postnatal dönem etkileri. Dizdar, Evrim Alyamaç; Ömer Erdeve; Uğur Dilmen // Cocuk Sagligi ve Hastaliklari Dergisi;tem-eyl2011, Vol. 54 Issue 3, p182 

    Crimean-Congo hemorrhagic fever is a lethal tickborne viral infection seen particularly in Africa, the Middle East, Asia, and Eastern Europe. Clinical features include fatigue, headache, fever, and myalgia accompanied by severe bleeding. Ribavirin is currently the only treatment option, although...

  • Kırım Kongo Kanamalı AteÅŸi. Seçmeer, Gülten; Çelik, İstemi Han // Journal of Pediatric Infection / Cocuk Enfeksiyon Dergisi;Dec2010, Vol. 4 Issue 4, p152 

    Crimean-Congo hemorrhagic fever (CCHF) is a viral infection more frequently described during recent years in our country, and has a high mortality rate. The virüs is a member of the Nairovirus genus (family Bunyaviridae). CCHF was first described as a clinical entity in 1945 in the Soviet...

  • More AEs with addition of ribavirin in phase III ION trials.  // Reactions Weekly;Aug2015, Vol. 1565 Issue 1, p7 

    The article reports on data from the phase III ION trials, which shows that the incidence of adverse events (AEs) is increased by the addition of ribavirin (RBV) to ledipasvir/sofosbuvir, without providing additional efficacy.

  • Viral Hemorrhagic Fever.  // Annals of Internal Medicine;Jul84, Vol. 101 Issue 1, p73 

    Offers a guide on the initial management of suspected and confirmed cases of viral hemorrhagic fever. Types of viral hemorrhagic fever; Causes; Discussion on specific isolation techniques.

  • Clinical Case Definitions for Argentine Hemorrhagic Fever. Harrison, Lee H.; Halsey, Noel A.; McKee Jr., Kelly T.; Peters, Clarence J.; Barrera Oro, Julio G.; Briggiler, Ana Marie; Feuillade, Maria Rosa; Maiztegui, Julio I. // Clinical Infectious Diseases;5/1/1999, Vol. 28 Issue 5, p1091 

    Examines febrile patients with suspected Argentine hemorrhagic fever, focusing on developing practical case definitions for use as objective outcome measures for decisions about therapy. Clinical signs and symptoms; Laboratory findings; Administration of immune plasma therapy; Potential use of...

  • An evaluation of interferon in the treatment of hepatitis C virus infection. Guay, David R.P. // Formulary;Feb99, Vol. 34 Issue 2, p132 

    Assesses the efficacy and side effect profiles of interferon (IFN) with or without ribavirin in the treatment of hepatitis C virus (HCV)-infected patients in the United States. Serologic testing; Focus of therapy; Reduction of the biologic and virologic markers of HCV infection; Sustained...

  • Peginterferon-α-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C: A Phase II Open-Label Study. Sulkowski, M.; Reindollar, R.; Thomas, D.L.; Brinkley-Laughton, S.; Hudson, M.; Yu, J. // BioDrugs;2002, Vol. 16 Issue 2, p105 

    Background and aims: Addition of a 40kD polyethylene glycol moiety to interferon-α-2a [peginterferon-α-2a (40kD)] improves pharmacokinetic properties over those of standard interferon. We conducted a phase II study to assess the safety and initial efficacy of peginterferon-α-2a (40kD)...

  • Ribavirin and acute bronchiolitis in infancy. Milner, A.D. // BMJ: British Medical Journal (International Edition);10/22/88, Vol. 297 Issue 6655, p998 

    Examines the efficacy of ribavirin as a treatment for acute bronchiolitis in infancy. Adverse effects of ribavirin; Implications for the administration of ribavirin to previously healthy babies with bronchiolitis; Prevalence and mortality of acute bronchiolitis in infancy.

  • Long-term efficacy of ribavirin plus interferon alfa for chronic hepatitis C. D.G.; Greenwald, David // Cortlandt Forum;04/25/97, Vol. 10 Issue 4, p32 

    Looks into a study by M.Y. Lai, J.H. Kao, et al published in `Gastroenterology' which evaluated interferon-alpha alone and combined with ribavirin in the treatment of chronic hepatitis C. Percentage of success of both protocols; Side effects; Low levels of success of interferon-alpha;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics